Vivos Therapeutics
Vivos Therapeutics' revenue rose 16.1% to $17 million in fiscal 2025. Its operating margin was −114.0%, down from −74.3% a year earlier. Free cash flow was −$18 million. The diluted share count rose 104.7%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
Vivos Therapeutics lost money in fiscal 2025: a net loss of $21 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 24 | 4 | 2 | 6 | 2 |
| Debt incl. finance leases | 1 | — | 1 | 1 | 1 |
| Net debt (negative means net cash) | −23 | — | −0 | −5 | −1 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.1x | — | — | 0.1x | — |
| Interest coverage | −1,455.9x | −12,515.5x | — | −1,241.2x | −14.2x |
| Current ratio | 3.6x | 0.8x | 0.3x | 1.5x | 0.2x |
| Quick ratio | 3.6x | 0.8x | 0.3x | 1.5x | 0.2x |
Cash flow
Projections
Project Vivos Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $1.8 million of Vivos Therapeutics shares on the open market, and none sold any.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Mar 31, 2026 | V-Co Investors 3 LLC10% owner | Bought | 1,353,625 | $1.34 | $1.8 million | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | 4 of 9 | 3 of 9 |
| Rule of 40 | −106.2% | −79.3% | −84.9% |
| Altman Z'' | −42.01 | −24.92 | −25.19 |
| Accruals ratio | −13.4% | 12.0% | −29.2% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Fail |
| Cash from operations exceeds net income | Pass | Fail | Pass |
| Debt fell relative to assets | — | Pass | Pass |
| Current ratio rose | Fail | Pass | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | Pass | Pass |
| Revenue rose relative to assets | Pass | Pass | Fail |
| F-score | — | 4 of 9 | 3 of 9 |
Compare
Put Vivos Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Vivos Therapeutics | FY25 | 16.1% | −114.0% | −100.9% | — | — | 3 | |
| Nephros | FY25 | 32.7% | 6.1% | — | — | — | — | Compare |
| Profound Medical | FY25 | 50.7% | −256.3% | −238.4% | −304.9% | — | 5 | Compare |
| QT Imaging Holdings | FY25 | 287.9% | −23.4% | −48.0% | −130.7% | — | 4 | Compare |
| Spectral AI | FY25 | −33.6% | −43.8% | — | — | — | — | Compare |
7 years of figures
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 11 | 13 | 17 | 16 | 14 | 15 | 17 |
| Revenue growth | — | 14.7% | 29.2% | −5.1% | −13.9% | 8.9% | 16.1% |
| Gross profit | 9 | 10 | 13 | 10 | 8 | 9 | 10 |
| Research and development | — | — | 0 | 0 | 0 | 0 | 0 |
| Operating income | −11 | −12 | −20 | −25 | −17 | −11 | −20 |
| Net income | −11 | −12 | −20 | −24 | −14 | −11 | −21 |
| Diluted EPS (US$) | −23.75 | −35.00 | −24.00 | −25.90 | −11.14 | −2.22 | −2.07 |
| Diluted shares (millions) | 0 | 0 | 1 | 1 | 1 | 5 | 10 |
| Cash flow | |||||||
| Cash from operations | −5 | −6 | −16 | −20 | −12 | −13 | −15 |
| Capital expenditure | 0 | 0 | 2 | 1 | 1 | 1 | 2 |
| Free cash flow | −6 | −6 | −18 | −21 | −13 | −13 | −18 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 2 | 2 | 3 | 2 | 1 | 1 | 1 |
| Balance sheet at fiscal year end | |||||||
| Cash and short-term investments | 0 | 18 | 24 | 4 | 2 | 6 | 2 |
| Debt incl. finance leases | 4 | 1 | 1 | — | 1 | 1 | 1 |
| Total assets | 8 | 25 | 34 | 14 | 11 | 15 | 25 |
| Total liabilities | 9 | 8 | 8 | 9 | 10 | 7 | 27 |
| Shareholders' equity | −3 | 17 | 26 | 5 | 0 | 8 | −2 |
| Margins and ratios | |||||||
| Gross margin | 76.0% | 79.7% | 74.7% | 62.5% | 59.9% | 60.0% | 60.4% |
| Operating margin | −92.8% | −92.2% | −120.7% | −156.2% | −125.3% | −74.3% | −114.0% |
| Net margin | −94.4% | −92.3% | −120.2% | −148.8% | −98.4% | −74.1% | −121.4% |
| Free cash flow margin | −48.4% | −44.4% | −107.4% | −128.0% | −92.4% | −88.2% | −100.9% |
| Rule of 40 (growth + FCF margin) | — | −29.7% | −78.2% | −133.1% | −106.2% | −79.3% | −84.9% |
| Return on capital | — | — | — | — | — | −616.7% | — |
| Return on equity | — | −172.6% | −95.6% | −157.2% | −521.2% | −266.2% | −655.0% |
| Return on assets | — | −73.3% | −68.8% | −100.6% | −111.1% | −85.6% | −104.7% |
| Net debt to EBITDA | — | — | — | — | — | — | — |